Skip to main content

Table 5 Univariate analysis of the predictors for the 30-day mortality

From: Clinical experience with tigecycline in the treatment of hospital-acquired pneumonia caused by multidrug resistant Acinetobacter baumannii

Variables Deatha n = 23 Survivala n = 54 OR (95% CI) p
Demographic parameters
 Age, year 63.0 (18.5) 61.8 (16.5)   0.644
 Female gender 9 (39.1%) 16 (29.6%) 1.53 (0.55–4.24) 0.415
Comorbidities
 Hepatic dysfunction 0 (0.0%) 2 (3.7%) 0.69 (0.60–0.81) 1.000
 Renal insufficiency 1 (4.3%) 6 (11.1%) 0.36 (0.41–3.21) 0.667
 Chronic pulmonary disease 6 (26.1%) 15 (27.8%) 0.92 (0.30–2.78) 0.879
 Heart disease 2 (8.7%) 11 (20.4%) 0.37 (0.08–1.83) 0.323
 Diabetes mellitus 2 (8.7%) 2 (3.7%) 2.48 (0.33–18.75) 0.578
 Immune compromise 2 (8.7%) 3 (5.6%) 1.62 (0.25–10.40) 0.632
 Malignancy 2 (8.7%) 5 (9.3%) 0.93 (0.17–5.20) 1.000
 Hypoproteinemia 0 (0.0%) 2 (3.7%) 0.69 (0.60–0.81) 1.000
 Surgery 5 (21.7%) 11 (20.4%) 1.09 (0.33–3.58) 1.000
Clinical conditions
 CURB65 score, mean ± SD 2.7 (1.1) 1.7 (0.8)   0.001
 Mechanical ventilation 21 (91.3%) 27 (50.0%) 10.5 (2.24–49.24) 0.001
 Albumin 32.2 (4.9) 32.1 (4.3)   0.916
Microbiology
 Bacteremia 5 (21.7%) 2 (3.7%) 7.22 (1.29–40.54) 0.022
 Tigecycline resistance 16 (69.6%) 19 (35.2%) 0.24 (0.08–0.68) 0.006
 Airway eradication of MDRAB 5 (27.8%) 19 (48.7%) 0.40 (0.12–1.35) 0.137
Tigecycline treatment
Duration, days 10.0 (6.6) 12.4 (5.8)   0.014
Combination therapy
 With sulbactam 19 (82.6%) 45 (83.3%) 0.95 (0.26–3.47) 1.000
 With carbapenems 1 (4.3%) 3 (5.6%) 0.77 (0.08–7.84) 1.000
 With amikacin 1 (4.3%) 2 (3.8%) 1.16 (0.10–13.46) 1.000
 With fluoroquinolones 1 (4.3%) 3 (5.6%) 0.77 (0.08–7.84) 1.000
 Delayed tigecycline treatment 6 (26.1%) 15 (27.8%) 0.92 (0.30–2.77) 0.879
  1. Abbreviations: OR odd ratio, CI confidence interval, MDRAB multi-drug-resistant Acinetobacter baumannii
  2. aCategorical data are n (%) of subject, continuous data are expressed as mean (standard deviation)